Ruxolitinib is effective in the treatment of a patient with refractory T‐ALL

T‐cell acute lymphoblastic leukemia (T‐ALL) is a rare, aggressive T‐cell malignancy. Chemotherapy alone cures only 25‐45% of the cases, thus, novel treatment agents and strategies are urgently needed. We assessed the efficacy of ruxolitinib in a patient with a cutaneous relapse after allogeneic bloo...

Descripción completa

Detalles Bibliográficos
Autores principales: Jaramillo, Sonia, Hennemann, Hannah, Horak, Peter, Teleanu, Veronica, Heilig, Christoph E., Hutter, Barbara, Stenzinger, Albrecht, Glimm, Hanno, Goeppert, Benjamin, Müller‐Tidow, Carsten, Fröhling, Stefan, Schönland, Stefan, Schlenk, Richard F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175749/
https://www.ncbi.nlm.nih.gov/pubmed/35846099
http://dx.doi.org/10.1002/jha2.143

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175749/
https://www.ncbi.nlm.nih.gov/pubmed/35846099
http://dx.doi.org/10.1002/jha2.143

Ejemplares similares